Draximage MAA Market Report 2026

Draximage MAA Market Overview

• The Draximage MAA market growth in the historic period has been driven by prevalence of pulmonary disorders, adoption of nuclear imaging techniques • Market expansion is supported by growth in respiratory disease burden, expansion of diagnostic imaging centers • Growth Driver: Rising Lung Cancer Incidence Driving Growth In The Draximage MAA Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Draximage MAA Market?

Draximage MAA is a radiopharmaceutical product used in nuclear medicine for lung imaging. It contains macro-aggregated albumin (MAA) tagged with technetium-99m, enabling ventilation/perfusion (V/Q) lung scans to assess pulmonary function. The radiolabeled particles are injected and tracked with a gamma camera to evaluate lung function and detect abnormalities. The main types of indication for draximage MAA are lymphatic mapping and sentinel lymph node biopsy. Lymphatic mapping using draximage MAA helps identify lymph nodes draining specific body areas, aiding cancer diagnosis and guiding surgical planning by detecting potential cancer spread. It is distributed by various distribution channels, such as hospital pharmacies, radiopharmacy services, and outpatient surgical centers, and used by several end users, including hospitals, clinics, ambulatory care, and home care.

What Is The Draximage MAA Market Growth Forecast?

The growth in the forecast period can be attributed to growth in respiratory disease burden, expansion of diagnostic imaging centers, improved gamma camera technology, rising early diagnosis focus, healthcare investment growth. Major trends in the forecast period include rising use of nuclear medicine imaging, expansion of lung function diagnostics, growing demand for v/q scans, advancements in radiopharmaceuticals, strengthening of hospital imaging services.

Global Draximage MAA Market Segmentation

1) By Indication: Lymphatic Mapping, Sentinel Lymph Node Biopsy 2) By Distribution Channel: Hospital Pharmacies, Radiopharmacy Services, Outpatient Surgical Centers 3) By End-User: Hospitals, Clinics, Ambulatory Care, Home Care

What Are The Drivers Of The Draximage MAA Market?

The increasing incidence of lung cancer is expected to fuel the growth of the draximage MAA market going forward. Lung cancer is a disease that originates in the lungs, marked by abnormal and uncontrolled cell growth that may spread to other areas of the body. Lung cancer is increasing due to a combination of factors, including the continued prevalence of smoking, exposure to environmental pollutants such as air pollution and secondhand smoke, occupational hazards like asbestos and radon, and the aging population. Draximage MAA helps in lung cancer by serving as a radiopharmaceutical used in positron emission tomography (PET) imaging to assist in the diagnosis, staging, and monitoring of treatment responses, enabling more accurate assessments of lung cancer and improving patient management strategies. For instance, in January 2024, according to the American Cancer Society, a US-based non-profit organization, approximately 234,580 new lung cancer cases were found in the U.S., including 116,310 men and 118,270 women, and 125,070 deaths, including 65,790 men and 59,280 women, highlighting a slightly higher incidence in women but greater mortality in men. Therefore, the increasing incidence of lung cancer drives the growth of the draximage MAA industry. The rising demand for medical imaging is set to propel the growth of the draximage MAA market moving forward. Medical imaging involves the use of techniques to produce visual images of the inside of the body for diagnostic and therapeutic purposes. The demand for medical imaging is driven by several factors, including an aging population, the prevalence of chronic diseases, improved healthcare infrastructure, and a shift toward minimally invasive procedures. Draximage MAA helps medical imaging by providing a radiopharmaceutical used in scintigraphy to visualize and assess pulmonary function, enabling enhanced imaging accuracy for detecting abnormalities such as pulmonary embolisms and assessing lung conditions, ultimately aiding in more precise diagnosis and treatment planning. For instance, in May 2023, according to the National Health Service, a UK-based government department, the number of magnetic resonance imaging (MRI) activities referred by general practitioners increased from 8,695 in January 2022 to 8,745 in January 2023. Moreover, in May 2023, according to the National Health Service, a UK-based government department, there were 43.4 million imaging tests reported in England in the 12 months from February 2022 to January 2023. Therefore, the rising demand for medical imaging is driving the growth of the draximage MAA industry. The growing geriatric population is significantly driving the growth of the draximage MAA market in the future. The geriatric population refers to individuals who are typically aged 65 years and older, often considered to be in the later stages of life. The geriatric population is increasing due to several factors, primarily the aging of the global population, improvements in healthcare, and advancements in medical treatments that have extended life expectancy. Draximage MAA helps the geriatric population by providing a radiopharmaceutical used in medical imaging to accurately assess pulmonary function, detect conditions like pulmonary embolisms, and monitor respiratory health, which is particularly crucial for older adults who may have multiple comorbidities and require precise diagnosis for effective treatment planning. For instance, in January 2024, according to the Population Reference Bureau, a Kenya-based nonprofit organization, the population of Americans aged 65 and older is expected to grow from 58 million in 2022 to 82 million by 2050, a 47% increase. This age group’s share of the overall population is also projected to rise from 17% to 23% during the same period. Therefore, the growing geriatric population drives the growth of the draximage MAA industry.

Key Players In The Global Draximage MAA Market

Major companies operating in the draximage maa market are Jubilant Draximage Inc.

Regional Insights

North America was the largest region in the draximage MAA market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Draximage MAA Market?

The draximage MAA market consists of sales of draximage MAA with human serum albumin and draximage MAA radiolabeled. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Draximage MAA Market Report 2026?

The draximage maa market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the draximage maa industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.